PPS for the prevention of potential adverse effects caused by CD3 specific binding domains

US9486475B2 · kind B2 · utility

Assignee

• AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

• Peter Kufer · Munich, DE
• Dirk Nagorsen · Munich, DE
• Juergen Scheele · Munich, DE
• Gerhard Zugmaier · Munich, DE
• Matthias Klinger · Gilching, DE
• Patrick Hoffmann · Munich, DE
• Virginie Naegele · Munich, DE
• Elaine-Pashupati Dopfer · Munich, DE

Key dates

• Filing date: Feb 8, 2014
• Grant date: Nov 8, 2016
• Expiry date: Feb 8, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a pentosanpolysulfate (PPS) or a pharmaceutically acceptable salt thereof for use in the amelioration, treatment, or prevention of adverse neurological events caused by administering an antibody or fragment thereof comprising a CD3 binding domain, including a CD19 x CD3 bispecific single chain antibody, such as blinatumomab. PPS is a semi-synthetically produced heparin-like macromolecular carbohydrate derivative, which chemically and structurally resembles glycosaminoglycans. Kits comprising a PPS, an antibody or fragment thereof comprising a CD3 binding domain, and instructions for administration, which indicate that the PPS is to be employed for the amelioration, treatment or prevention of adverse neurological events caused by administering the antibody or fragment thereof comprising said CD3 binding domain, are also disclosed.